News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,932 Results
Type
Article (54905)
Company Profile (222)
Press Release (633795)
Multimedia
Podcasts (136)
Webinars (16)
Section
Business (184877)
Career Advice (2756)
Deals (34004)
Drug Delivery (137)
Drug Development (79737)
Employer Resources (170)
FDA (16918)
Job Trends (15701)
News (324752)
Policy (33129)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2890)
Accelerated approval (37)
Adcomms (35)
Allergies (154)
Alliances (47595)
ALS (176)
Alzheimer's disease (1752)
Antibody-drug conjugate (ADC) (344)
Approvals (17119)
Artificial intelligence (575)
Autoimmune disease (179)
Automation (42)
Bankruptcy (349)
Best Places to Work (11929)
BIOSECURE Act (20)
Biosimilars (208)
Biotechnology (146)
Bladder cancer (164)
Brain cancer (66)
Breast cancer (670)
Cancer (5008)
Cardiovascular disease (449)
Career advice (2345)
Career pathing (41)
CAR-T (305)
CDC (60)
Celiac Disease (2)
Cell therapy (807)
Cervical cancer (35)
Clinical research (68433)
Collaboration (1838)
Company closure (5)
Compensation (572)
Complete response letters (77)
COVID-19 (2972)
CRISPR (101)
C-suite (909)
Cystic fibrosis (150)
Data (6323)
Decentralized trials (2)
Denatured (35)
Depression (150)
Diabetes (530)
Diagnostics (6959)
Digital health (48)
Diversity (9)
Diversity, equity & inclusion (39)
Drug discovery (268)
Drug pricing (216)
Drug shortages (32)
Duchenne muscular dystrophy (244)
Earnings (72942)
Editorial (66)
Employer branding (22)
Employer resources (154)
Events (107218)
Executive appointments (1029)
FDA (20140)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1536)
Gene editing (214)
Generative AI (54)
Gene therapy (657)
GLP-1 (1111)
Government (5079)
Grass and pollen (8)
Guidances (386)
Healthcare (19662)
HIV (69)
Huntington's disease (49)
IgA nephropathy (87)
Immunology and inflammation (290)
Immuno-oncology (62)
Indications (113)
Infectious disease (3273)
Inflammatory bowel disease (198)
Inflation Reduction Act (16)
Influenza (126)
Intellectual property (257)
Interviews (516)
IPO (15257)
IRA (54)
Job creations (4107)
Job search strategy (1930)
JPM (70)
Kidney cancer (17)
Labor market (80)
Layoffs (635)
Leadership (41)
Legal (7584)
Liver cancer (99)
Longevity (15)
Lung cancer (682)
Lymphoma (384)
Machine learning (44)
Management (62)
Manufacturing (835)
MASH (171)
Medical device (14143)
Medtech (14196)
Mergers & acquisitions (19771)
Metabolic disorders (1394)
Multiple sclerosis (172)
NASH (21)
Neurodegenerative disease (362)
Neuropsychiatric disorders (98)
Neuroscience (3076)
Neurotech (1)
NextGen: Class of 2026 (6987)
Non-profit (4950)
Now hiring (59)
Obesity (681)
Opinion (317)
Ovarian cancer (167)
Pain (213)
Pancreatic cancer (231)
Parkinson's disease (299)
Partnered (33)
Patents (492)
Patient recruitment (510)
Peanut (60)
People (57270)
Pharmaceutical (39)
Pharmacy benefit managers (32)
Phase 1 (21276)
Phase 2 (29854)
Phase 3 (22891)
Pipeline (5498)
Policy (328)
Postmarket research (2580)
Preclinical (8318)
Press Release (63)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (285)
Rare diseases (925)
Real estate (5845)
Recruiting (75)
Regulatory (25168)
Reports (41)
Research institute (2599)
Resumes & cover letters (417)
Rett syndrome (28)
RNA editing (16)
RSV (87)
Schizophrenia (156)
Series A (257)
Series B (201)
Service/supplier (10)
Sickle cell disease (103)
Special edition (25)
Spinal muscular atrophy (169)
Sponsored (40)
Startups (3678)
State (1)
Stomach cancer (20)
Supply chain (111)
Tariffs (98)
The Weekly (99)
Vaccines (1151)
Venture capital (99)
Weight loss (462)
Women's health (89)
Worklife (22)
Date
Today (82)
Last 7 days (508)
Last 30 days (2211)
Last 365 days (29622)
2026 (3818)
2025 (29979)
2024 (34399)
2023 (39265)
2022 (50190)
2021 (54917)
2020 (54214)
2019 (48017)
2018 (36744)
2017 (32937)
2016 (32503)
2015 (37108)
2014 (28743)
2013 (23745)
2012 (25519)
2011 (26205)
2010 (23386)
Location
Africa (965)
Alabama (88)
Alaska (7)
Arizona (258)
Arkansas (14)
Asia (40612)
Australia (6927)
California (11173)
Canada (3044)
China (1126)
Colorado (478)
Connecticut (472)
Delaware (315)
Europe (93678)
Florida (1583)
Georgia (350)
Hawaii (4)
Idaho (64)
Illinois (868)
India (70)
Indiana (534)
Iowa (21)
Japan (431)
Kansas (121)
Kentucky (42)
Louisiana (28)
Maine (81)
Maryland (1348)
Massachusetts (7557)
Michigan (335)
Minnesota (603)
Mississippi (6)
Missouri (141)
Montana (31)
Nebraska (28)
Nevada (120)
New Hampshire (84)
New Jersey (2893)
New Mexico (31)
New York (2883)
North Carolina (1449)
North Dakota (10)
Northern California (5373)
Ohio (322)
Oklahoma (22)
Oregon (42)
Pennsylvania (2142)
Puerto Rico (24)
Rhode Island (45)
South America (1313)
South Carolina (64)
South Dakota (1)
Southern California (4420)
Tennessee (177)
Texas (1659)
United States (38786)
Utah (354)
Vermont (1)
Virginia (264)
Washington D.C. (80)
Washington State (903)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
688,932 Results for "helsinn healthcare sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
February 18, 2026
·
2 min read
Press Releases
Helsinn and ESTEVE expand their partnership extending the Distribution and Licence Agreement for AKYNZEO® and ALOXI® to Austria
February 9, 2026
·
4 min read
Press Releases
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
February 11, 2026
·
4 min read
Press Releases
Helsinn announces new Executive Leadership Team as it celebrates 50 years
January 13, 2026
·
3 min read
Press Releases
Battelle Named Key Subcontractor to SA-TECH for Mission Support Services Contract at U.S. Army Dugway Proving Ground
January 30, 2026
·
3 min read
Press Releases
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
November 24, 2025
·
19 min read
Press Releases
Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders’ Equity Requirement
January 26, 2026
·
4 min read
Press Releases
Urteste S.A. launches European multicenter clinical study of the Panuri test
November 7, 2025
·
4 min read
Press Releases
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
April 2, 2025
·
2 min read
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.
June 24, 2024
·
5 min read
1 of 68,894
Next
